The latest new contracts, like Esteve’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ESTEVE signs a licensing agreement for Increlex® treatment of severe primary insulin-like growth factor 1 deficiency
ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals for Increlex® with global rights, except for USA. Increlex® is a biologic product used for the long-term treatment of growth failure in patients aged 2 to 18 years due to severe primary insulin-like-growth-factor-1 deficiency (SPIGFD). The medication is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is designated as an 'orphan medicine' for rare diseases.
Company Information
Company
Esteve
Location
Barcelona, Catalonia, Spain
About
Esteve is a global pharmaceutical company headquartered in Barcelona, focused on providing solutions for unmet medical needs. With a history dating back to 1929, ESTEVE is committed to improving people's lives through its pharmaceutical products and services.
BarcelonaManufacturingBiotechnologyHealth CarePharmaceutical